
A four-day meeting in the EMA's Committee for Medicinal Products for Human Use (CHMP) has resulted in a host of recommendations on Friday.
The commission has lined up eight new drugs for approval, including Leo Pharma's tralokinumab with the commercial name Adtralza. Now, they await formal approval from the EU Commission. Ordinarily, this is seen as a formality, since the commission only goes against the EMA's suggestions on very rare occasions.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app